Adcendo to Participate in Expert ADC Panel Debate at BIO-Europe 2024

On October 29, 2024 Adcendo ApS ("Adcendo"), a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, reported that its CEO, Michael Pehl will join fellow antibody-drug-conjugate (ADC) industry leaders and experts on a panel discussion at the 30th Annual BIO-Europe conference, held in Stockholm, Sweden, from 4th-6th November 2024 (Press release, ADCendo, OCT 29, 2024, View Source [SID1234647529]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The panel discussion at this year’s BIO-Europe event will explore the rapidly expanding ADC sector and provide insights into the current landscape. Panellists will share perspectives on the latest innovations and challenges facing ADC development, as well as the future of ADCs and their potential to reshape the paradigm of precision medicine.

Panel discussion details:

Panel Title: "Two for the Price of One!" The ADC arena
Speaker: Michael Pehl, CEO of Adcendo
Panel Date and Time: Tuesday 5 November, 2024, 14:00 CET
Venue: Stockholmsmässan, Mässvägen 1, 125 30 Älvsjö, Stockholm, Sweden
Location: Room K2

2024 has been a transformative year for Adcendo as the Company shortly transitions into becoming a clinical-stage biotech with two first-in-class programs, ADCE-T02, targeting Tissue Factor (TF) in multiple epithelial cancers, and ADCE-D01, targeting uPARAP in patients with metastatic and/or unresectable STS, entering the clinical stage of development. A Clinical Trial Notification has been submitted for ADCE-T02 in Australia with FPI planned in Q4 2024, and Adcendo has recently received US FDA IND clearance to commence a first-in-human Phase I/II study (ADCElerate-01 Trial) of ADCE-D01.

Leidos Reports Strong Third Quarter 2024 Results and Raises Full-Year Guidance

On October 29, 2024 Leidos Holdings, Inc. (NYSE: LDOS) reported financial results for the third quarter of fiscal year 2024 (Press release, Leidos, OCT 29, 2024, View Source [SID1234649390]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Continued improvement in operating performance across all segments drove excellent revenue growth, record margins for net income and adjusted EBITDA, substantial earnings growth, strong cash flow, and robust bookings," said Leidos Chief Executive Officer Tom Bell. "These results demonstrate clearly how our collaborative and innovative workforce is focused on consistent execution for our customers and shareholders. With a healthy balance sheet, improving business development performance, and emerging ‘North Star’ strategy, Leidos is well positioned to deliver robust and sustainable returns as we move forward."

Revitope Enters into a License Agreement for Next-generation T Cell Engagement Technology

On October 29, 2024 Revitope Oncology Inc. (Revitope), a biotechnology company advancing a new class of precision cancer immunotherapies, reported that it has signed a license agreement providing Genmab A/S (Genmab) access to Revitope’s conditional TCE technology, TwoGATE (Press release, Revitope Oncology, OCT 29, 2024, View Source [SID1234647495]). Genmab is granted exclusive rights to utilize TwoGate for multiple drug target pairs during a multi-year research period, including the option to take up to three exclusive licenses for worldwide development and commercialization of the resulting products.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TwoGATE leverages the dual antigen binding requirement of a unique split paratope that assembles on the tumor cell surface to potently engage T cells with high precision, potentially addressing key areas of unmet need in the treatment of solid tumors.

"The unique blending of precision protein engineering in TwoGATE with target pairs that are exquisitely tailored to solid tumors with high unmet need, offers the potential to transform treatment of solid tumors by allowing TCEs to be dosed at levels that achieve significant efficacy without inducing systemic toxicities," said Werner Meier, Chief Scientific Officer of Revitope. "Genmab is the ideal partner to bring this potential to patients."

"We are thrilled to partner with Genmab, a leading biotechnology company," said Mark Clement, Chief Operating Officer of Revitope. "In deploying our cutting-edge TwoGATE technology platform together with Genmab’s robust antibody engineering and development capabilities, Revitope aims to strengthen Genmab’s pipeline, thereby aiding the transformation of cancer treatment."

Financial Terms

Revitope will receive an upfront payment of USD $9 million and, on a target pair-by-target pair basis, is eligible to receive option-exercise fees and development, regulatory and commercial milestone payments up to USD $600 million -if all three options are triggered- plus tiered, single-digit royalties on commercial sales.

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

On October 29, 2024 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, reported that the Company will present at two upcoming scientific conferences (Press release, Sensei Biotherapeutics, OCT 29, 2024, View Source [SID1234647496]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference and Presentation Details:

PEGS Europe: Protein and Antibody Engineering Summit, November 5-7, 2024, Barcelona, Spain

Title: Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditionally Active Monoclonal Antibody
Presenter: Edward van der Horst, Ph.D., Chief Scientific Officer
Session: Antibody-Based Cancer Therapies
Date and time: Tuesday, November 5, 2024, 9:00 a.m. CET (Central European Time)

Society for Immunotherapy Cancer (SITC) (Free SITC Whitepaper) 39th Annual Meeting, November 6-10, Houston Texas

Title: Spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indications
Presenter: F. Donelson Smith, Ph.D., Senior Director, Biologics Discovery & Early Development
Presentation Type: Poster
Abstract Number: 70
Date and Time: Saturday, November 9, 2024, 12:15–1:45 p.m. & 7:00-8:30 p.m. CST.
Location: Level 1-Exhibit Halls AB (George R. Brown Convention Center)

Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024

On October 29, 2024 Alligator Bioscience AB ("Alligator") (ATORX) and Aptevo Therapeutics ("Aptevo") (Nasdaq: APVO) reported that new, positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 will be presented in a poster session on Friday, November 8, 2024, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2024 (SITC) (Free SITC Whitepaper), taking place November 6th – 10th, 2024 in Houston, Texas (Press release, Alligator Bioscience, OCT 29, 2024, View Source [SID1234647474]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Poster number: #673
Title: Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4×4-1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological activity
Presenter: Thomas Marron, MD, PhD
Date/Time: Friday, November 8th from 12:15-1:45 and 5:30-7:00 PM US Central time.

About the Trial
The ALG.APV-527 Phase 1 trial is a multi-center, multi-cohort, open-label dose-escalation trial that will include administration of ALG.APV-527 up to six escalating dose levels in a 3+3 design*. The trial is enrolling adult patients with multiple solid tumor types/histologies likely to express the 5T4 antigen. ALG.APV-527 will be given intravenously once every two weeks. The trial will assess the safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of ALG.APV-527.

*The 3+3 design proceeds in cohorts of three patients treated at increasing dose levels. Dose escalation stops when at least two out of three or six patients experience dose limiting toxicities (DLTs) at that dose level.

About ALG.APV-527
ALG.APV-527 is a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4. This has the potential to be clinically important because 4-1BB can stimulate the immune cells (antitumor-specific T cells and NK cells) involved in tumor control, making 4-1BB a particularly compelling target for cancer immunotherapy. 5T4 is an oncofetal tumor associated antigen overexpressed on numerous solid tumors including non-small-cell lung carcinoma (NSCLC), breast, head and neck, cervical, renal, gastric, and colorectal cancer.